In Brief: FDA ingrown toenail drug "feedback" meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA ingrown toenail drug "feedback" meeting: With Schering- Plough about addition of sodium sulfide 1% to the ingrown toenail relief OTC drug monograph will be held Jan. 20 at the request of Schering-Plough, which markets Dr. Scholl's foot care products. The company petitioned the agency for the monograph amendment in May 1994; FDA has raised concerns about the ingredient's safety. Schering-Plough Scientific and Regulatory Affairs Senior VP John Clayton, PhD, and Clinical Research/Regulatory Affairs VP Ronald Garutti, MD, will attend. The meeting will take place at 9201 Corporate Blvd., S200, Rockville, Md., starting at 9:30 a.m. For more information on the meeting, contact FDA's Melvin Lessing at (301) 827-2271...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning